Walleye Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Walleye Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-169,000	Closed	-$16.9M	–	5211
2025 Q3	$16.9M	Buy	169,000 +124,000	+276%	+$11.2M	0.06%	310
2025 Q2	$3.73M	Hold	45,000	–	–	0.01%	1070
2025 Q1	$3.65M	Sell	45,000 -12,400	-22%	-$1.11M	0.02%	993
2024 Q4	$5.17M	Sell	57,400 -4,500	-7%	-$436K	0.01%	1046
2024 Q3	$6.12M	Hold	61,900	–	–	0.01%	1024
2024 Q2	$5.74M	Sell	61,900 -159,900	-72%	-$14.3M	0.01%	1185
2024 Q1	$21M	Sell	221,800 -90,000	-29%	-$8.35M	0.04%	400
2023 Q4	$27.8M	Buy	311,800 +50,000	+19%	+$3.71M	0.06%	231
2023 Q3	$19.1M	Buy	261,800 +50,000	+24%	+$3.99M	0.05%	277
2023 Q2	$17.6M	Buy	+211,800	New	+$17.7M	0.06%	199
2022 Q4	–	Sell	-3,000	Closed	-$238K	–	3689
2022 Q3	$238K	Buy	+3,000	New	+$253K	﹤0.01%	1995

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Walleye Capital's XBI Position: Q1 2025 in Review

Walleye Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 134,006 shares — an estimated $12M sold.

Walleye Capital first reported a position in XBI in Q4 2020 and held it in 5 quarters. The position peaked at $15.9M in Q3 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

Walleye Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 134,006 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $12M.
Walleye Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 5 quarters.
Walleye Capital's State Street SPDR S&P Biotech ETF position peaked at $15.9M in Q3 2024.
682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.